Remicade
Pfizer’s Litfulo significantly improved repigmentation in nonsegmental vitiligo
NSV is a chronic autoimmune disease where the immune system attacks melanin-producing cells, leading to a loss of pigment
J&J’s Darzalex combination treatment for untreated multiple myeloma recommended by NICE
Around 33,000 people in the UK are currently living with multiple myeloma, an incurable type of blood cancer
Pfizer and Valneva’s application for Lyme disease vaccine candidate validated by EMA
There are currently no approved human vaccines for Lyme disease
Johnson & Johnson announces change in senior leadership role
Tom Cavanaugh has been appointed as Executive Vice President, Worldwide Chairman Innovative Medicine
Pfizer announces phase 3 results for nonsegmental vitiligo treatment
Litfulo delivered significant, clinically meaningful improvements for both face and body
Johnson & Johnson commits $5.5bn to end remaining talc litigation
The resolution comes after plaintiffs were unable to prove that J&J’s talc products caused their ovarian cancer
Pfizer’s Talzenna plus Xtandi gets FDA Priority Review for metastatic prostate cancer
The phase 3 trial showed greater than 50% improvement in radiographic progression-free survival
Pfizer announces phase 3 results for potential non-small cell lung cancer treatment
Patients who had received only one prior line of systemic therapy showed a stronger trend for overall survival and progression-free survival
J&J’s Erleada prostate cancer study shows significant reduction in risk of metastasis
Erleada plus hormone therapy significantly improved key short- and long-term clinical outcomes
Pfizer and Innovent Biologics agree on deal worth up to $10.5bn
The companies plan to research and develop 12 new cancer treatments
J&J’s Icotyde approved by US FDA for plaque psoriasis
Plaque psoriasis affects over 125 million people worldwide
J&J’s nipocalimab gets FDA Fast Track designation for lupus
The autoimmune disease affects approximately three to five million people globally